Pacira BioSciences, Inc. PCRX iovera° — Total net product sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s iovera° — total net product sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s iovera° — total net product sales?
- Pacira BioSciences, Inc. (PCRX) reported iovera° — total net product sales of $6.18M in Q1 2026.
- How has Pacira BioSciences, Inc.'s iovera° — total net product sales changed year-over-year?
- Pacira BioSciences, Inc.'s iovera° — total net product sales increased by 20.6% year-over-year, from $5.12M to $6.18M.
- What is the long-term trend for Pacira BioSciences, Inc.'s iovera° — total net product sales?
- Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s iovera° — total net product sales has grown at a 10.6% compound annual growth rate (CAGR), from $16.16M to $24.18M.
- What does iovera° — total net product sales mean?
- This metric represents the total revenue generated from the sale of a specific medical device or therapeutic product line after accounting for returns, allowances, and discounts. It serves as a primary indicator of market adoption and commercial performance for the product segment. Tracking this figure allows investors to evaluate the growth trajectory and revenue contribution of the specific technology within the company's broader portfolio.